Cardiac transplantation in amyloidosis – who, when, and (then) what

When is a heart transplant considered in amyloidosis, and who qualifies? In this session, we break down how doctors evaluate candidacy, how disease type (ATTR vs AL) and timing impact outcomes, and what life looks like after transplant. We’ll cover risks, recovery, and how transplant fits with modern therapies so you can make informed decisions with your care team.

Speaker:  Dr. Hasan Siddiqi is an advanced heart failure cardiologist who is the director of the cardiac amyloidosis program and assistant professor of medicine at Vanderbilt Univ Medical Center in Nashville, TN. He is board certified in internal medicine, cardiology, heart failure, cardiac transplantation and echocardiography. Dr. Siddiqi is involved in multiple studies and trials in the treatment of cardiac amyloidosis patients, as well as being developing a novel research program for cardiac amyloidosis at Vanderbilt University. In addition to cardiac amyloidosis, Dr. Siddiqi also manages patients with heart failure, ventricular assist devices and heart transplantation in his clinic, in the ICU and inpatient units. Dr. Siddiqi graduated from Harvard College with a degree in neurobiology, then went to the Univ of Michigan for medical school and his masters in clinical research, followed by residency at the University of Pennsylvania. He then pursued cardiology, heart failure and transplantation fellowships at Brigham and Women’s Hospital/Harvard Medical School, following which he was appointed assistant professor of medicine at Vanderbilt Univ. He lives with his wife and two young children in Nashville, TN.